Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on March 3, 2011, regarding events occurring on February 28, 2011. The filing addresses significant changes in the company's senior financial leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and associated compensatory arrangements.
Material Changes
- Departure: Patricia L. Allen resigned as Vice President, Finance, and Treasurer effective February 28, 2011. She is expected to consult for the company for one year to assist with the transition.
- Appointment: Michael P. Mason was appointed as Vice President, Finance, Treasurer, and Principal Financial and Accounting Officer effective February 28, 2011.
- Compensatory Arrangement: In connection with his appointment, Mr. Mason was granted a stock option award to purchase 25,000 shares of common stock at an exercise price of $10.98 per share. The options vest 25% on the first anniversary of the grant date, with the remainder vesting ratably over the subsequent three years.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on business performance, risks, contingencies, or unusual items. The document is limited to the disclosure of officer changes.
Investor Verification Checklist
- Verify the transition plan for financial operations following Ms. Allen's departure.
- Review the vesting schedule and exercise price ($10.98) of the 25,000 stock options granted to Mr. Mason.
- Confirm Mr. Mason's prior tenure and roles within Alnylam (Corporate Controller and Senior Director of Finance) to assess internal continuity.